PsoProtect is an international registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis: . The EDF is member of PsoProtect.


PsoProtect seeks to rapidly improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. This information will inform clinicians when assessing risk and treating COVID-19 in patients with psoriasis. 


Uploading case information to the website is quick. The online case report form collects only de-identified data and is closely aligned with that of similar efforts in IBD and Rheumatology to enable valuable cross-disease analyses. We will provide real-time updates of the cases reported for the benefit of the whole clinical community. 


This international registry is keen to ensure robust participation of the international clinical community in PsoProtect in order to maximize the clinical utility of the data collected.

We encourage our EDF members to report their cases of COVID-19 in psoriasis via the website

PsoProtect releases summary data from first 200 cases across 22 countries / Please keep reporting your cases of COVID-19 in psoriasis to PsoProtect.


PsoProtect, the global web-based registry for healthcare professionals to report cases of COVID-19 (confirmed or suspected) in psoriasis, has just released summary data from the first 200 cases across 22 countries on the PsoProtect website ( ).   


We would like to thank you for your kind cooperation.


Yours sincerely,


Prof. Alexander Enk       
EDF President

    Prof. Nick Reynolds
    EDF Secretary-General


We are delighted to inform you that the PsoProtectMe website is now LIVE in Spanish, Portuguese, Italian, Polish, Chinese and Japanese, as well as English - just select your preferred language on